Table 5 Sensitivity analysis results comparing all medications
From: Competing treatments for migraine: a headache for decision-makers
|  | Costs (£) | QALYs | Incremental costs (£) | Incremental QALYs | ICER: cost per QALY gained (£) | Comparison |
|---|---|---|---|---|---|---|
a) 5-year time horizon | ||||||
 Probabilistic results – discounted | ||||||
  Topiramate | £3,159 | 3.1717 | - | - | - | - |
  Placebo | £3,491 | 3.0348 | £333 | -0.1369 | Dominated | Placebo vs. Topiramate |
  BTA | £6,383 | 3.2497 | £3,224 | 0.0779 | £41,366 | BTA vs. Topiramate |
  Fremanezumab (monthly) | £16,039 | 3.2483 | £9,656 | -0.0014 | Dominated | Fremanezumab (monthly) vs. BTA |
  Fremanezumab (quarterly) | £16,120 | 3.2283 | £9,737 | -0.0214 | Dominated | Fremanezumab (quarterly) vs BTA |
  Eptinezumab 100 | £16,145 | 3.2163 | £9,762 | -0.0334 | Dominated | Eptinezumab 100 vs. BTA |
  Galcanezumab | £16,577 | 3.2071 | £10,194 | -0.0425 | Dominated | Galcanezumab vs. BTA |
  Eptinezumab 300 | £42,184 | 3.2573 | £35,801 | 0.0076 | £4,707,286 | Eptinezumab 300 vs. BTA |
b) Lifetime horizon | ||||||
 Probabilistic results—discounted | ||||||
  Topiramate | £13,351 | 15.7628 | - | - | - | - |
  Placebo | £15,138 | 15.1467 | £1,787 | -0.6161 | Dominated | Placebo vs. Topiramate |
  BTA | £16,381 | 16.2613 | £3,030 | 0.4985 | £6,077 | BTA vs. Topiramate |
  Fremanezumab (monthly) | £27,469 | 16.1774 | £11,088 | -0.0840 | Dominated | Fremanezumab (monthly) vs. BTA |
  Eptinezumab 100 | £27,846 | 16.1319 | £11,465 | -0.1294 | Dominated | Fremanezumab (quarterly) vs BTA |
  Fremanezumab (quarterly) | £27,840 | 16.0931 | £11,459 | -0.1682 | Dominated | Eptinezumab 100 vs. BTA |
  Galcanezumab | £28,194 | 16.1418 | £11,813 | -0.1195 | Dominated | Galcanezumab vs. BTA |
  Eptinezumab 300 | £57,609 | 16.3428 | £41,228 | 0.0815 | £505,711 | Eptinezumab 300 vs. BTA |
c) Utility inputs—van-Hout crosswalk algorithm | ||||||
 Probabilistic results—discounted | ||||||
  Topiramate | £1,627 | 1.4063 | - | - | - | - |
  Placebo | £1,723 | 1.3807 | 96 | -0.0256 | Dominated | Placebo vs. Topiramate |
  BTA | £3,656 | 1.4475 | £2,029 | 0.0412 | £49,265 | BTA vs. Topiramate |
  Fremanezumab (monthly) | £10,161 | 1.4608 | £6,505 | 0.0133 | Extendedly dominated | Fremanezumab (monthly) vs. BTA |
  Fremanezumab (quarterly) | £10,193 | 1.4532 | £32 | -0.0076 | Dominated | Fremanezumab (quarterly) vs Fremanezumab (monthly) |
  Eptinezumab 100 | £10,221 | 1.4346 | £60 | -0.0262 | Dominated | Eptinezumab 100 vs. Fremanezumab (monthly) |
  Galcanezumab | £10,650 | 1.4436 | £489 | -0.0172 | Dominated | Galcanezumab vs. Fremanezumab (monthly) |
Eptinezumab 300 | £27,411 | 1.4512 | £17,250 | -0.0096 | £6,353,726 | Eptinezumab 300 vs. BTA |
d) Using MMDs instead of MHDs | ||||||
 Probabilistic results—discounted | ||||||
  Topiramate | £1,585 | 1.3220 | - | - | - | - |
  Placebo | £1,731 | 1.2245 | £146 | -0.0975 | Dominated | Placebo vs. Topiramate |
  BTA | £3,645 | 1.3566 | £2,060 | 0.0346 | £59,596 | BTA vs. Topiramate |
  Erenumab 70 | £8,944 | 1.3754 | £5,299 | 0.0188 | Extendedly dominated | Erenumab 70 vs BTA |
  Erenumab 140 | £8,949 | 1.3749 | £5 | -0.0005 | Dominated | Erenumab 140 vs Erenumab 70 |
  Fremanezumab (monthly) | £10,072 | 1.3916 | £1,128 | 0.0162 | £183,732 | Fremanezumab (monthly) vs. BTA |
  Fremanezumab (quarterly) | £10,140 | 1.3644 | £68 | -0.0272 | Dominated | Fremanezumab (quarterly) vs Fremanezumab (monthly) |
  Eptinezumab 100 | £10,188 | 1.3584 | £116 | -0.0332 | Dominated | Eptinezumab 100 vs. Fremanezumab (monthly) |
  Galcanezumab | £10,610 | 1.3584 | £538 | -0.0332 | Dominated | Galcanezumab vs. Fremanezumab (monthly) |
  Eptinezumab 300 | £27,377 | 1.3850 | £17,305 | -0.0065 | Dominated | Eptinezumab 300 vs. Fremanezumab (monthly) |
e) Reducing costs of MAbs by 50% | ||||||
 Probabilistic results—discounted | ||||||
  Topiramate | £1,625 | 1.4078 | - | - | - | - |
  Placebo | £1,729 | 1.3415 | £105 | -0.0663 | Dominated | Placebo vs. Topiramate |
  BTA | £3,653 | 1.4218 | £2,028 | 0.0140 | £144,881 | BTA vs. Topiramate |
  Fremanezumab (monthly) | £5,835 | 1.4395 | £2,182 | 0.0177 | £123,111 | Fremanezumab (monthly) vs. BTA |
  Fremanezumab (quarterly) | £5,869 | 1.4321 | £34 | -0.0074 | Dominated | Fremanezumab (quarterly) vs Fremanezumab (monthly) |
  Eptinezumab 100 | £5,896 | 1.4210 | £61 | -0.0185 | Dominated | Eptinezumab 100 vs. Fremanezumab (monthly) |
  Galcanezumab | £6,097 | 1.4272 | £261 | -0.0123 | Dominated | Galcanezumab vs. Fremanezumab (monthly) |
  Eptinezumab 300 | £14,455 | 1.4358 | £8,620 | -0.0037 | Dominated | Eptinezumab 300 vs. Fremanezumab (monthly) |